T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Mondelez International
MDLZ
|
+$841M |
| 2 |
Liberty Global Class C
LBTYK
|
+$752M |
| 3 |
Apple
AAPL
|
+$720M |
| 4 |
Tesla
TSLA
|
+$713M |
| 5 |
NXP Semiconductors
NXPI
|
+$648M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$1.2B |
| 2 |
AGN
Allergan plc
AGN
|
+$1.03B |
| 3 |
Gilead Sciences
GILD
|
+$917M |
| 4 |
Pfizer
PFE
|
+$901M |
| 5 |
Nike
NKE
|
+$872M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 19.88% |
| 2 | Consumer Discretionary | 14.86% |
| 3 | Financials | 14.2% |
| 4 | Technology | 12.51% |
| 5 | Industrials | 9.12% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
951
Alamo Group
ALG
$2.01B
| $30.4M | 0.01% |
461,254
-2,590
| -0.6% | -$152K |
|
952
Puma Biotechnology
PBYI
$459M
| $30.3M | 0.01% |
1,016,874
-689,348
| -40% | -$21.6M |
|
|
COR
953
DELISTED
Coresite Realty Corporation
COR
| $30.2M | 0.01% |
341,025
+46,425
| +16% | +$3.58M |
|
|
VGR
954
DELISTED
Vector Group Ltd.
VGR
| $30.2M | 0.01% |
2,309,581
-66,402
| -3% | -$835K |
|
955
Azenta
AZTA
$1.47B
| $30.2M | 0.01% |
2,692,244
-77,300
| -3% | -$810K |
|
|
CONE
956
DELISTED
CyrusOne Inc Common Stock
CONE
| $30.2M | 0.01% |
542,546
+56,376
| +12% | +$2.71M |
|
957
Saga Communications
SGA
$64.6M
| $30.1M | 0.01% |
762,207
+7,600
| +1% | +$318K |
|
958
NovoCure
NVCR
$2.05B
| $30.1M | 0.01% |
2,580,593
-7,872
| -0.3% | -$98.6K |
|
959
FRP Holdings
FRPH
$425M
| $30M | 0.01% |
1,741,400
+1,400
| +0.1% | +$23.6K |
|
|
LXFT
960
DELISTED
Luxoft Holding, Inc.
LXFT
| $30M | 0.01% |
575,881
-2,650
| -0.5% | -$155K |
|
961
Red Rock Resorts
RRR
$3.73B
| $29.9M | 0.01% |
+1,360,813
| New | +$27.7M |
|
962
Nordson
NDSN
$17.3B
| $29.9M | 0.01% |
357,727
+40,890
| +13% | +$3.29M |
|
963
Trane Technologies
TT
$105B
| $29.9M | 0.01% |
469,240
-5,500
| -1% | -$354K |
|
|
NBL
964
DELISTED
Noble Energy, Inc.
NBL
| $29.9M | 0.01% |
832,730
-1,254,113
| -60% | -$44.1M |
|
|
DISCK
965
DELISTED
Discovery, Inc. Series C Common Stock
DISCK
| $29.8M | 0.01% |
1,251,190
-82,500
| -6% | -$2.18M |
|
966
Bausch Health
BHC
$2.32B
| $29.8M | 0.01% |
1,483,154
-665,647
| -31% | -$18.8M |
|
|
GTS
967
DELISTED
Triple-S Management Corporation
GTS
| $29.6M | 0.01% |
1,275,591
-368
| -0% | -$8.55K |
|
968
Healthpeak Properties
DOC
$14.2B
| $29.6M | 0.01% |
917,555
-2,767
| -0.3% | -$85.9K |
|
969
RingCentral
RNG
$5.25B
| $29.5M | 0.01% |
1,494,932
+179,300
| +14% | +$3.39M |
|
970
Snap-on
SNA
$21.1B
| $29.4M | 0.01% |
186,404
-130,501
| -41% | -$20.7M |
|
971
Fastenal
FAST
$59.9B
| $29.4M | 0.01% |
2,645,580
-8,080
| -0.3% | -$92.3K |
|
972
Kinross Gold
KGC
$32.6B
| $29.3M | 0.01% |
5,983,150
+5,954,050
| +20,461% | +$28.4M |
|
973
Protolabs
PRLB
$2.17B
| $29.2M | 0.01% |
506,466
+1,800
| +0.4% | +$120K |
|
974
Freeport-McMoran
FCX
$96.9B
| $28.9M | 0.01% |
2,593,819
-2,645,900
| -50% | -$29.3M |
|
|
COHR
975
DELISTED
Coherent Inc
COHR
| $28.5M | 0.01% |
310,760
-1,390
| -0.4% | -$128K |
|
Similar funds
T. Rowe Price Associates's Q2 2016 Portfolio in Review
As of Q2 2016, T. Rowe Price Associates held 2,596 positions worth $472B, up 0.75% from $468B the previous quarter. Its ten largest holdings account for 16% of the portfolio.
T. Rowe Price Associates's Q2 2016 filing shows 95 new, 1,094 increased, 954 reduced and 84 closed positions. Its largest new stake was American Tower Corporation: 2,223,765 shares worth $246M. The largest sale was Alexion Pharmaceuticals, an estimated $1.2B.
By sector, the portfolio is most concentrated in Healthcare at 20% of assets, down from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
- T. Rowe Price Associates's largest Q2 2016 buy was American Tower Corporation: 2,223,765 shares worth $246M.
- T. Rowe Price Associates added most to Mondelez International in Q2 2016, an estimated $841M increase.
- T. Rowe Price Associates's biggest Q2 2016 reduction was Alexion Pharmaceuticals, cutting an estimated $1.2B.
- T. Rowe Price Associates fully exited BAXALTA INC COM STK (DE) in Q2 2016, selling an estimated $750M.
- T. Rowe Price Associates's ten largest holdings make up 16% of its $472B portfolio in Q2 2016.
- T. Rowe Price Associates opened 95 new positions and closed 84 in Q2 2016.
- T. Rowe Price Associates's portfolio value rose 0.75% quarter-over-quarter to $472B.
Based on T. Rowe Price Associates's 13F filing for Q2 2016, filed 15 Aug 2016.